阿霉素
纳米医学
药理学
体内分布
体内
体外
依托泊苷
化学
材料科学
化疗
生物物理学
癌症研究
生物化学
纳米技术
纳米颗粒
医学
生物
内科学
生物技术
作者
Lingling Shan,Guizhen Gao,Weiwei Wang,Wei Tang,Zhantong Wang,Zhèn Yáng,Wenpei Fan,Guizhi Zhu,Kefeng Zhai,Orit Jacobson,Yunlu Dai,Xiaohong Chen
出处
期刊:Biomaterials
[Elsevier]
日期:2019-05-01
卷期号:210: 62-69
被引量:68
标识
DOI:10.1016/j.biomaterials.2019.04.032
摘要
Nanomedicine has become a promising approach to improve cancer chemotherapy. It remains a major challenge how to enhance anti-drug efficacy and reduce side effects of anti-cancer drugs. Herein, we report a self-assembled nanoplatform (FDEP NPs) by integration of doxorubicin (DOX) and epigallocatechin-3-O-gallate (EGCG) with the help of coordination between Fe3+ ions and polyphenols. The EGCG from FDEP NPs could inhibit the expression of carbonyl reductase 1 (CBR1) protein and thereby inhibit the doxorubicinol (DOXOL) generation from DOX both in vitro and in vivo, thus the efficacy of DOX to cancerous cells is improved significantly. More importantly, the FDEP NPs could reduce cardiac toxicity and the DOX mediated toxicity to blood cells due to the repression of DOXOL production. Moreover, the blood half-life of FDEP NPs is longer than 23 h as determined by positron emission tomography (PET) imaging of biodistribution of radiolabelled NPs and HPLC measurement of plasma level of DOX, ensuring high tumor accumulation of FDEP NPs by enhanced permeability and retention (EPR) effect. The FDEP NPs also exhibited much improved antitumor effect over free drugs. Our work sheds new light on the engineering of nanomaterials for combination chemotherapy and may find unique clinical applications in the near future.
科研通智能强力驱动
Strongly Powered by AbleSci AI